2001
DOI: 10.1006/nbdi.2001.0439
|View full text |Cite
|
Sign up to set email alerts
|

Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
65
1

Year Published

2007
2007
2017
2017

Publication Types

Select...
5
2
2

Relationship

1
8

Authors

Journals

citations
Cited by 133 publications
(68 citation statements)
references
References 24 publications
2
65
1
Order By: Relevance
“…A fluorescent microscope equipped with a cooled CCD camera and Neurolucida software (Version 7; MicroBrightField Inc., Williston, VT) were used to analyze the sections and for acquisition of images under virtual slice mode. NFTs were identified by means of the standard Gallyas silver-impregnation method (10).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…A fluorescent microscope equipped with a cooled CCD camera and Neurolucida software (Version 7; MicroBrightField Inc., Williston, VT) were used to analyze the sections and for acquisition of images under virtual slice mode. NFTs were identified by means of the standard Gallyas silver-impregnation method (10).…”
Section: Methodsmentioning
confidence: 99%
“…A single tau gene mutation induces NFT formation and neuronal loss with 100% penetration. Moreover, overexpression of human FTDP-17 tau induces NFT formation, neuronal loss, and behavioral deficits in mice (5)(6)(7)(8)(9)(10)(11)(12).…”
Section: Nftsmentioning
confidence: 99%
“…Surprisingly, none of these plaque producing transgenic models display NFTs or ADtype neurodegenerative changes (Van Leuven, 2000), suggesting that additional mechanisms underlie AD. Although NFTs are seen in independent transgenic models overexpressing mutant tau isoforms, which are linked to tauopathies in humans (Lewis et al, 2000;Gotz et al, 2001;Tanemura et al, 2001;Tatebayashi et al, 2002), there are no known tau mutations associated with AD.…”
Section: Introductionmentioning
confidence: 99%
“…TauV337M [52]: Mice express low level synthesis of 4R MAPT with the V337M mutation (1/10 of endogenous mouse MAPT) driven by the promoter of platelet-derived growth factor (PDGF). The development of neurofibrillary pathology in these mice suggests the nature of tau rather than absolute intracellular tau concentrations drives pathology.…”
Section: Bri-a 40 and Bri-a 42mentioning
confidence: 99%